Going past the data for temozolomide

J. Lee Villano, Nathalie Letarte, Linda R. Bressler

Research output: Contribution to journalComment/debate

3 Scopus citations


The benefit of six cycles of adjuvant temozolomide was documented in a randomized phase III (EORTC-NCIC CE.3) trial, and this therapy, following combined temozolomide and radiation, is the standard of care for patients with newly diagnosed glioblastoma. We comment on the differences in the length of adjuvant therapy in both clinical practice and national studies (e.g. RTOG 0825), usually doubling the length in the EORTC/NCIC study, and relate to historic adjuvant trials for solid tumors.

Original languageEnglish
Pages (from-to)1113-1115
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Issue number4
StatePublished - Apr 2012


  • Adjuvant therapy
  • Brain tumor
  • Glioblastoma
  • Temozolomide

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)


Dive into the research topics of 'Going past the data for temozolomide'. Together they form a unique fingerprint.

Cite this